Treatment of comorbid tobacco use in people with serious mental illness.
Lising-Enriquez
Katrina
K
Division of Addiction Psychiatry, Department of Psychiatry, University of Toronto, Schizophrenia Program, Centre for Addiction and Mental Health Toronto, Ontario.
George
Tony P
TP
D000328:Adult; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000008:administration & dosage; D015897:Comorbidity; D003376:Counseling; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009538:Nicotine / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000453:epidemiology*; D012907:Smoking / Q000453:epidemiology* / Q000628:therapy*; D016540:Smoking Cessation; D000068580:Varenicline
D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline